Objective: To estimate the prevalence of ADHD and determine an effective screening test for ADHD in a population-seeking treatment for cannabis use disorders. Method: The Conners Adult ADHD Diagnostic Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV; CAADID) was used to generate sensitivity and specificity data for ADHD screening tests, which were then administered to 99 participants seeking treatment for cannabis use disorders to estimate ADHD prevalence. Results: The prevalence estimated from the Wender Utah Rating Scale (WURS) was 45% (sensitivity = 0.88, sensitivity of 0.75), from the Conners Adult ADHD Rating Scale (CAARS) 34% (sensitivity = 0.80, specificity = 0.91), from the WURS + CAARS 36% (sensitivity = 0.71, specificity = 0.95), and from the Adult ADHD Self-Report Scale (ASRS) 46% (sensitivity = 0.61, specificity = 0.86). Conclusion: The prevalence of ADHD in adults seeking treatment for cannabis use disorders is estimated to be between 34% and 46%. The WURS paired with the CAARS provides excellent sensitivity and specificity for the diagnosis of ADHD in this population.
Objective: To estimate the prevalence of ADHD and determine an effective screening test for ADHD in a population-seeking treatment for cannabis use disorders. Method: The Conners Adult ADHD Diagnostic Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV; CAADID) was used to generate sensitivity and specificity data for ADHD screening tests, which were then administered to 99 participants seeking treatment for cannabis use disorders to estimate ADHD prevalence. Results: The prevalence estimated from the Wender Utah Rating Scale (WURS) was 45% (sensitivity = 0.88, sensitivity of 0.75), from the Conners Adult ADHD Rating Scale (CAARS) 34% (sensitivity = 0.80, specificity = 0.91), from the WURS + CAARS 36% (sensitivity = 0.71, specificity = 0.95), and from the Adult ADHD Self-Report Scale (ASRS) 46% (sensitivity = 0.61, specificity = 0.86). Conclusion: The prevalence of ADHD in adults seeking treatment for cannabis use disorders is estimated to be between 34% and 46%. The WURS paired with the CAARS provides excellent sensitivity and specificity for the diagnosis of ADHD in this population.
Authors: Karen L Hanson; Jennifer L Winward; Alecia D Schweinsburg; Krista Lisdahl Medina; Sandra A Brown; Susan F Tapert Journal: Addict Behav Date: 2010-06-13 Impact factor: 3.913
Authors: Katelijne van Emmerik-van Oortmerssen; Geurt van de Glind; Wim van den Brink; Filip Smit; Cleo L Crunelle; Marije Swets; Robert A Schoevers Journal: Drug Alcohol Depend Date: 2011-12-30 Impact factor: 4.492
Authors: Ronald C Kessler; Lenard Adler; Minnie Ames; Olga Demler; Steve Faraone; Eva Hiripi; Mary J Howes; Robert Jin; Kristina Secnik; Thomas Spencer; T Bedirhan Ustun; Ellen E Walters Journal: Psychol Med Date: 2005-02 Impact factor: 7.723
Authors: Ronald C Kessler; Lenard Adler; Russell Barkley; Joseph Biederman; C Keith Conners; Olga Demler; Stephen V Faraone; Laurence L Greenhill; Mary J Howes; Kristina Secnik; Thomas Spencer; T Bedirhan Ustun; Ellen E Walters; Alan M Zaslavsky Journal: Am J Psychiatry Date: 2006-04 Impact factor: 18.112
Authors: Jodi M Gilman; John K Kuster; Sang Lee; Myung Joo Lee; Byoung Woo Kim; Nikos Makris; Andre van der Kouwe; Anne J Blood; Hans C Breiter Journal: J Neurosci Date: 2014-04-16 Impact factor: 6.167
Authors: Matthijs G Bossong; J Martijn Jansma; Hendrika H van Hell; Gerry Jager; René S Kahn; Nick F Ramsey Journal: PLoS One Date: 2013-07-31 Impact factor: 3.240
Authors: Christina A Brezing; C Jean Choi; Martina Pavlicova; Daniel Brooks; Amy L Mahony; John J Mariani; Frances R Levin Journal: Am J Addict Date: 2018-02-19
Authors: Alessandro Pallucchini; Marco Carli; Marco Scarselli; Icro Maremmani; Giulio Perugi Journal: Int J Environ Res Public Health Date: 2021-01-21 Impact factor: 3.390